IOVA jumps 21% in four sessions as Barclays cites upside
IOVance Biotherapeutics (IOVA) shares have risen more than 21% over the past four sessions. Barclays expects the rally to continue as investors await an important lung cancer update; stock was up nearly 2% in pre-market trading and is on track to climb above $10 for the first time since an unspecified prior period.
Iovance Biotherapeutics (IOVA) shares have gained more than 21% over the past four sessions, and Barclays said it expects the advance to continue as investors wait for an important lung cancer update. IOVA shares were up nearly 2% in pre-market trading and are on track to move above $10 for the first time since …